USE IN PREGNANCY
When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, uniretic® should be discontinued as soon as possible. See WARNINGS, Fetal/Neonatal Morbidity and Mortality.
(moexipril HCl / hydrochlorothiazide)
7.5 mg/12.5 mg
15 mg/12.5 mg
15 mg/25 mg
uniretic® (moexipril hydrochloride/hydrochlorothiazide) is a combination of an angiotensin-converting enzyme (ACE) inhibitor, moexipril hydrochloride, and a diuretic, hydrochlorothiazide. Moexipril hydrochloride is a fine white to off-white powder. It is soluble (about 10% weight-to-volume) in distilled water at room temperature.
uniretic® is indicated for treatment of patients with hypertension. This fixed combination is not indicated for the initial therapy of hypertension (DOSAGE AND ADMINISTRATION).
In using uniretic®, consideration should be given to the fact that another ACE inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that uniretic® does not have a similar risk (see WARNINGS, Neutropenia/Agranulocytosis). In addition, ACE inhibitors, for which adequate data are available, cause a higher rate of angioedema in black than in nonblack patients (see WARNINGS, Angioedema).
Media Articles Related to Uniretic (Moexipril / Hydrochlorothiazide)
EHRs Take Center Stage in Battle to Control Hypertension
Source: MedPageToday.com - medical news plus CME for physicians [2015.03.27]
(MedPage Today) -- "Home-grown" electronic health record largely credited for better BP control.
Hypertension Becoming More Deadly?
Source: MedPage Today Cardiovascular [2015.03.26]
(MedPage Today) -- Cited more often as a factor on death certificates.
Vitamin D 'ineffective as treatment for hypertension'
Source: Cardiovascular / Cardiology News From Medical News Today [2015.03.19]
Researchers report that vitamin D supplementation does not work as an antihypertensive agent and cannot be recommended to control high blood pressure.
ACC: Folate Supplements Cut Strokes in Hypertension
Source: MedPage Today Neurology [2015.03.19]
(MedPage Today) -- Hypertensive patients with low blood folate levels gain big benefit.
Expanding blood pressure screenings beyond primary care can improve hypertension detection
Source: Hypertension News From Medical News Today [2015.03.16]
Expanding blood pressure screenings to non-primary care settings can help identify more patients with high blood pressure, commonly called hypertension, and could contribute to better hypertension...
Published Studies Related to Uniretic (Moexipril / Hydrochlorothiazide)
Comparison between moexipril and atenolol in obese postmenopausal women with hypertension. [1998.09.20]
The present study investigated the effect of the new ACE-inhibitor moexipril versus the beta 1-adrenergic blocker atenolol on metabolic parameters, adverse events (AEs) and sitting systolic (SSBP) and sitting diastolic blood pressure (SDBP) in obese postmenopausal women with hypertension (stage I and II)...
Antihypertensive treatment in postmenopausal women: results from a prospective, randomized, double-blind, controlled study comparing an ACE inhibitor (moexipril) with a diuretic (hydrochlorothiazide). [1998.05]
The present study was designed to compare the safety and efficacy of the new angiotensin-converting enzyme inhibitor moexipril with that of hydrochlorothiazide (HCTZ) in postmenopausal women with mild-to-moderate hypertension. After a 4-week single-blind placebo period, 97 postmenopausal hypertensive women (42-74 years of age) with a sitting diastolic blood pressure (SDBP) of 95-114 mm Hg were randomized to receive either once daily moexipril 15 mg or HCTZ 25 mg for a 12-week double-blind treatment period.
Antihypertensive effectiveness of a very low fixed-dose combination of moexipril and hydrochlorothiazide. [1998.03]
The antihypertensive and metabolic effects of a fixed combination of very low dose of moexipril (MO), an angiotensin-converting enzyme (ACE) inhibitor, and hydrochlorothiazide (HCTZ) were tested in a multicenter, placebo (PBO) controlled, double-blind, parallel study of men (M) and women (W) with mild to moderate essential hypertension.
Usefulness of moexipril and hydrochlorothiazide in moderately severe essential hypertension. [1997.04]
The purpose of this study was to assess the efficacy and tolerability of the angiotensin-converting enzyme inhibitor moexipril alone and in combination with hydrochlorothiazide versus hydrochlorothiazide monotherapy in patients with stage II and III essential hypertension.There is also an additive effect when combining the two agents that lowers BP more significantly than either monotherapy.
Antihypertensive treatment with moexipril plus HCTZ vs metoprolol plus HCTZ in patients with mild-to-moderate hypertension. [1997.02]
Combination therapy with the new ACE inhibitor moexipril plus hydrochlorothiazide (HCTZ) results in significant blood pressure (BP) reductions. This study compares the efficacy and safety of moexipril plus HCTZ to that of a standard combination treatment in patients with mild-to-moderate hypertension...
Page last updated: 2015-03-27